Download PDF
Dtsch Med Wochenschr 2008; 133(37): 1848-1852
DOI: 10.1055/s-0028-1082808
Übersicht | Review article
Nephrologie, Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Nieren und Diabetes

The kidneys and diabetesC. Rüster1 , A. Sämann1 , G. Wolf1
  • 1Klinik für Innere Medizin III, Friedrich-Schiller-Universität Jena
Further Information

Publication History

5.3.2008

24.4.2008

Publication Date:
03 September 2008 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Diabetes mellitus - Nephropathie - Proteinurie - Kreatinin

Key words

diabetes mellitus - nephropathy - proteinuria - creatinine

Literatur

  • 1 Adler A I, Stevens R J, Manley S E. et al . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).  Kidney Int. 2003;  63 225-232
    Google Scholar
  • 2 Barnett A H, Bain S C, Bouter P. et al . Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.  N Engl J Med. 2004;  351 1952-1961
    Google Scholar
  • 3 Bertoni A G, Krop J S, Anderson G F, Brancati F L. Diabetes-related morbidity and mortality in a national sample of U.S. elders.  Diabetes Care. 2002;  25 471-475
    Google Scholar
  • 4 Deutsche Hochdruckliga e. V. DHL® – Deutsche Hypertonie Gesellschaft . Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie.  Nieren- und Hochdruckkrankheiten. 2005;  34 481-498
    Google Scholar
  • 5 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.  Lancet. 2000;  355 253-259
    Google Scholar
  • 6 European Society of Hypertension – European Society of Cardiology . Guidelines for the management of arterial hypertension.  J Hypertens. 2003;  21 1011-1053
    Google Scholar
  • 7 Fisher E B, Thorpe C T, Devellis B M, Devellis R F. Healthy coping, negative emotions, and diabetes management: a systematic review and appraisal.  Diabetes Educ. 2007;  33 1080-1103; discussion 1104 – 1086
    Google Scholar
  • 8 Frei U, Schober-Halstenberg H J. Nierenersatztherapie in Deutschland. QuaSi-Niere Jahresbericht 2005/2006, Berlin, Deutschland. 
    Google Scholar
  • 9 Gaede P, Vedel P, Parving H H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.  Lancet. 1999;  353 617-622
    Google Scholar
  • 10 Goede P, Lund-Andersen H, Parving H H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes.  N Engl J Med. 2008;  358 580-591
    Google Scholar
  • 11 Harding G K, Zhanel G G, Nicolle L E, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria.  N Engl J Med. 2002;  347 1576-1583
    Google Scholar
  • 12 Hasslacher C, Kempe P, Ritz E, Wolf G. Diabetische Nephropathie. DDG Praxis-Leitlinie.  Diabetologie. 2007;  2 S159-S162
    Google Scholar
  • 13 Helmchen U, Kneissler U, Velden J, Stahl R AK. Nierenbiopsiebefunde bei Diabetes mellitus.  Der Diabetologe. 2006;  2 419-431
    Google Scholar
  • 14 Kastelein J J, Akdim F, Stroes E S. et al . Simvastatin with or without ezetimibe in familial hypercholesterolemia.  N Engl J Med. 2008;  358 1431-1443
    Google Scholar
  • 15 Keech A, Simes R J, Barter P. et al . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study).  Lancet. 2005;  366 1849-1861
    Google Scholar
  • 16 MacIsaac R J, Panagiotopoulos S, McNeil K J. et al . Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?.  Diabetes Care. 2006;  29 1560-1566
    Google Scholar
  • 17 Meiland R, Geerlings S E, Stolk R P. et al . Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up.  Arch Intern Med. 2006;  166 2222-2227
    Google Scholar
  • 18 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals.  Lancet. 2002;  360 7-22
    Google Scholar
  • 19 National Institutes of Health .For Safety. NHLBI Changes Intensive Blood Sugar Treatment Strategy in Clinical Trial of Diabetes and Cardiovascular Disease. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id = 2551. last vistited 2.3.2008. 
    Google Scholar
  • 20 Ogawa Y, Goto T, Tamasawa N. et al . Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy.  Diabetes Res Clin Pract. 2008;  79 357-361
    Google Scholar
  • 21 Pinkau T, Hilgers K F, Veelken R, Mann J F. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?.  J Am Soc Nephrol. 2004;  15 517-523
    Google Scholar
  • 22 Pucci L, Triscornia S, Lucchesi D. et al . Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients.  Clin Chem. 2007;  53 480-488
    Google Scholar
  • 23 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
    Google Scholar
  • 24 Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease.  J Am Soc Nephrol. 2006;  17 2985-2991
    Google Scholar
  • 25 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.  Diabetes Care. 2000;  23 Suppl 2 B21-29
    Google Scholar
  • 26 Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.  J Am Med Assoc. 2003;  290 2159-2167
    Google Scholar
  • 27 The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.  Diabetes. 1996;  45 1289-1298
    Google Scholar
  • 28 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. UK Prospective Diabetes Study Group.  BMJ. 1998;  317 703-713
    Google Scholar
  • 29 Tuomilehto J, Lindstrom J, Eriksson J G. et al . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
    Google Scholar
  • 30 Winocour P H. Effective diabetes care: a need for realistic targets.  BMJ. 2002;  324 1577-1580
    Google Scholar
  • 31 Wolf G, Muller N, Mandecka A, Muller U A. Association of diabetic retinopathy and renal function in patients with types 1 and 2 diabetes mellitus.  Clin Nephrol. 2007;  68 81-86
    Google Scholar
  • 32 Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management.  J Am Soc Nephrol. 2003;  14 1396-1405
    Google Scholar
  • 33 Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.  Kidney Int. 2005;  67 799-812
    Google Scholar

Prof. Dr. med. Gunter Wolf

Klinik für Innere Medizin III

Erlanger Allee 101

07740 Jena

Phone: 03641/9324300

Fax: 03641/9324302

Email: gunter.wolf@med.uni-jena.de

      >